Why the study?
Patients with type 2 diabetes mellitus can be affected by cardiac autonomic neuropathy, leading to increased morbidity and mortality.
This review summarizes current concepts, diagnosis, and treatments for cardiovascular autonomic neuropathy in type 2 diabetes, highlighting the potential of newer glycemic drugs to reduce sudden death.
Cardiac autonomic neuropathy signals higher mortality in T2DM; leaves open optimal use of emerging therapies.
Diabetes is one of the most common chronic pathologies around the world, involving treatment with general clinicians, endocrinologists, cardiologists, ophthalmologists, nephrologists and a multidisciplinary team. Patients with type 2 Diabetes Mellitus (T2DM) can be affected by cardiac autonomic neuropathy, leading to increased mortality and morbidity. In this review, we will present current concepts, clinical features, diagnosis, prognosis, and possible treatment. New drugs recently developed to reduce glycemic level presented a pleiotropic effect of reducing sudden death, suggesting a potential use in patients at risk.
No takes yet. Share an insight, caveat, or question.
Breder et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: